130 related articles for article (PubMed ID: 3744626)
1. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
Traeger A; Horváth T; Rechenbach C; Jávor T
Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
[TBL] [Abstract][Full Text] [Related]
2. Beta-adrenergic blockade affects initial drug distribution due to decreased cardiac output and altered blood flow distribution.
Avram MJ; Krejcie TC; Henthorn TK; Niemann CU
J Pharmacol Exp Ther; 2004 Nov; 311(2):617-24. PubMed ID: 15197245
[TBL] [Abstract][Full Text] [Related]
3. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
Branch RA; Shand DG; Wilkinson GR; Nies AS
J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (Catergen) in chronic alcoholic liver disease.
Pár A; Horváth T; Beró T; Kádas I; Pakodi F; Jávor T
Acta Physiol Hung; 1984; 64(3-4):449-54. PubMed ID: 6152369
[TBL] [Abstract][Full Text] [Related]
5. [Effect of propranolol on the ability of the liver to metabolize drugs in patients with hypertension].
Adamska-Dyniewska H; Gajewska B
Kardiol Pol; 1979; 22(1):7-11. PubMed ID: 423420
[No Abstract] [Full Text] [Related]
6. Proceedings: The influence of chronic liver disease on the elimination of d-propranolol, anti-pyrine, and indocyanine green.
Branch RA; James JA; Read AE
Gut; 1974 Oct; 15(10):837-8. PubMed ID: 4434964
[No Abstract] [Full Text] [Related]
7. Selective effects of a bacterial infection (Actinobacillus pleuropneumoniae) on the hepatic clearances of caffeine, antipyrine, paracetamol, and indocyanine green in the pig.
Monshouwer M; Witkamp RF; Nijmeijer SM; Pijpers A; Verheijden JH; Van Miert AS
Xenobiotica; 1995 May; 25(5):491-9. PubMed ID: 7571722
[TBL] [Abstract][Full Text] [Related]
8. The features of hepatic enzyme induction with glutethimide in man.
Jackson L; Homeida M; Roberts CJ
Br J Clin Pharmacol; 1978 Dec; 6(6):525-8. PubMed ID: 728322
[TBL] [Abstract][Full Text] [Related]
9. Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man.
Gachályi B; Tornyossy M; Vas A; Káldor A
Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):133-5. PubMed ID: 6103880
[TBL] [Abstract][Full Text] [Related]
10. Disorders of biotransformation during the progression of alcoholic liver disease.
Horváth T; Pár A; Past T; Beró T; Tapsonyi Z; Kádas I
Acta Med Hung; 1986; 43(4):351-7. PubMed ID: 3601579
[TBL] [Abstract][Full Text] [Related]
11. Hepatic drug clearance in patients with mild cystic fibrosis.
Kearns GL; Crom WR; Karlson KH; Mallory GB; Evans WE
Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
[TBL] [Abstract][Full Text] [Related]
12. Specific and dose-dependent enzyme induction by omeprazole in human beings.
Rost KL; Brösicke H; Heinemeyer G; Roots I
Hepatology; 1994 Nov; 20(5):1204-12. PubMed ID: 7927253
[TBL] [Abstract][Full Text] [Related]
13. Investigation of biotransformation capacity in patients with chronic liver diseases by pharmacokinetic methods: experimental trials.
Horváth T; Past T; Tatai Z; Pár A; Kádas I; Tapsonyi Z; Jávor T
Pol J Pharmacol Pharm; 1984; 36(4):361-71. PubMed ID: 6396596
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the functional reserve of the human liver by urinary D-glucaric acid excretion after vitamin C administration.
Hanaue H; Kanno K; Mukai M; Kubo H; Tobita K; Nakasaki H; Tajima T; Mitomi T; Endo R
Tokai J Exp Clin Med; 1993 Jun; 18(1-2):1-4. PubMed ID: 7940601
[TBL] [Abstract][Full Text] [Related]
15. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
[TBL] [Abstract][Full Text] [Related]
16. Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
Horváth T; Pár A; Beró T; Kádas I; Fábián C; Jávor T
Acta Med Hung; 1983; 40(4):203-13. PubMed ID: 6674914
[TBL] [Abstract][Full Text] [Related]
17. Effect of Fluosol-DA hemodilution on the kinetics of hepatically eliminated drugs.
Shrewsbury RP
Res Commun Chem Pathol Pharmacol; 1987 Mar; 55(3):375-96. PubMed ID: 3575876
[TBL] [Abstract][Full Text] [Related]
18. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
von Mandach U; Jost G; Preisig R
Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
[TBL] [Abstract][Full Text] [Related]
19. Research on the eventual enzymatic induction activity of cetiedil in rat and man.
Larousse C; Kergueris MF; Le Normand Y; Visset J
Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):195-9. PubMed ID: 7390670
[TBL] [Abstract][Full Text] [Related]
20. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
Hayes PC; Bouchier IA
Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
